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Prostaglandins are important regulators of female reproductive functions to which aldose
reductases exhibiting hydroxysteroid dehydrogenase activity also contribute. Our work on
the regulation of reproductive function by prostaglandins (PGs), lead us to the discovery that
AKR1B5 and later AKR1B1were highly efﬁcient and physiologically relevant PGF synthases.
PGE2 andPGF2α are themain prostanoids produced in the human endometriumand proper
balance in their relative production is important for normal menstruation and optimal fertil-
ity. Recent evidence suggests that PGE2/EP2 and PGF2α/FP may constitute a functional
dyad with physiological relevance comparable to the prostacyclin-thromboxane dyad in the
vascular system.We have recently reported that AKR1B1was expressed andmodulated in
association with PGF2α production in response to IL-1β in the human endometrium. In the
present study, we show that the human AKR1B1 (gene ID: 231) also known as ALDR1 or
ALR2 is a functional PGF2α synthase in different models of living cells and tissues. Using
human endometrial cells, prostate, and vascular smooth muscle cells, cardiomyocytes and
endothelial cells we demonstrate that IL-1β is able to up regulate COX-2 and AKR1B1 pro-
teins as well as PGF2α production under normal glucose concentrations. We show that
the promoter activity of AKR1B1 gene is increased by IL-1β particularly around the multiple
stress response region containing two putative antioxidant response elements adjacent
to TonE and AP1.We also show that AKR1B1 is able to regulate PGE2 production through
PGF2α acting on its FP receptor and that aldose reductase inhibitors like alrestatin, Statil
(ponalrestat), and EBPC exhibit distinct and characteristic inhibition of PGF2α production in
different cell models.The PGF synthase activity of AKR1B1 represents a new and important
target to regulate ischemic and inﬂammatory responses associated with several human
pathologies.
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INTRODUCTION
The human aldose reductase ALR2 gene AKR1B1 is a notorious
enzyme which has been associated with complications of diabetes
for more than four decades (Srivastava et al., 2005). AKR1B1
is considered as the rate limiting enzyme of the polyol path-
way responsible for the conversion of glucose into sorbitol. The
association of AKR1B1 with cardiovascular risks, neuropathies,
and nephropathies characteristic of diabetes is receiving increased
acceptance (Alexiou et al., 2009). However, the contribution of the
polyol pathway to the same complications is less convincing (Del
Corso et al., 2008). Indeed, while many factors including inﬂam-
mation induce increased expression and activity of AKR1B1, this
enzyme has very little afﬁnity for glucose at physiological concen-
trations and a detoxiﬁcation action involving reduction of lipid
peroxides has beenproposed (Srivastava et al.,2005).While search-
ing for the enzyme responsible for the production of PGF2α in the
endometrium, we made the serendipitous and unexpected dis-
covery that AKR1B5 (Madore et al., 2003) and later the human
aldose reductase AKR1B1 (Bresson et al., 2011) were highly func-
tional PGFS. Prostaglandins (PGs) are notorious mediators of
pain and inﬂammation also associated with proliferation of can-
cer cells. While the same mediators are recognized as primary
regulators of female reproductive function (ovulation, uterine
receptivity, implantation, and parturition) they also contribute
to occurrence of endometrial carcinomas, menorrhagia, dysmen-
orrhea, endometriosis, and premature labor. Among the different
PGs, PGE2 and PGF2α are the main prostanoids produced in the
human endometrium (Smith and Kelly, 1988; Sales and Jabbour,
2003a). PGs are synthesized from arachidonic acid (AA) and con-
verted to PGG2 and PGH2 by PGH synthases (PGHS), also known
as cyclooxygenases (COX). There are two documented isoforms of
PGHS in human, the constitutive COX-1 and the inducible COX-2
encoded by two distinct genes (Smith et al., 1996). PGH2 produced
by COXs is the common precursor of all PGs generated by spe-
ciﬁc terminal synthases such as PGF synthase for PGF2α and PGE
synthase for PGE2. The human terminal synthases responsible
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for the biosynthesis of PGE2 (Park et al., 2006), PGD2 (Zhou
et al., 2010), and PGI2 (Wu and Liou, 2005) are well charac-
terized, but only little is known for the enzyme responsible for
PGF2α production. Before our identiﬁcation of the PGF synthase
activity of aldo-ketoreductases (AKR) of the 1B family (Madore
et al., 2003; Bresson et al., 2011) only one AKR of the 1C fam-
ily, AKR1C3 was recognized as a functional PGF synthase in the
human (Suzuki-Yamamoto et al., 1999).
PGF2α is a biologically active prostanoid belonging to the
eicosanoid family of bioactive lipids (Narumiya and FitzGerald,
2001). Its biosynthesis occurs via different pathways involving
reduction of PGH2 by a 9,11-endoperoxyde reductase (Watan-
abe, 2002). Several PGFS have been identiﬁed in animals (Madore
et al., 2003), but until recently, AKR1C3 was the only isoform cur-
rently identiﬁed in human (Komoto et al., 2006). In the bovine
endometrium, using a cell-free system, we have demonstrated a
strong PGFS activity of puriﬁed recombinant AKR1B5 recently
renamed as bos taurus AKR1B1 (Gene ID: 317748) as well as
circumstantial association between its pattern of expression and
PGF2αproduction.This represents anewputative function for this
enzyme previously known for its 20α-HSD and glucose metab-
olism activities (Madore et al., 2003). The human and bovine
AKR1B1 (EC:1.1.1.21) both belong to the AKR1B family and
share 86% identity or homology. The human AKR1B1 (Gene ID:
231) also known as the aldose reductase or ALDR1belongs to the
AKR superfamily composed of 140 members divided into 15 fam-
ilies (Jin and Penning, 2007). AKR1B1 (EC:1.1.1.21) is primarily
known as the rate limiting enzyme for conversion of glucose to sor-
bitol in the polyol pathway, but recent studies revealed its ability to
convert a wide array of substrates including aldehydes generated
during lipid peroxidation and their glutathione (GSH) conjugates,
phospholipids, atherogenic lipids, and steroids (Srivastava et al.,
2005).
After identifying the bovine AKR1B1 as a potential PGFS
(Madore et al., 2003), we have shown circumstantial association
with PGF2α production in human endometrial cell lines (Chapde-
laine et al., 2006) and in decidualized stromal cells (Kang et al.,
2006). Later, the PGFS activity of mouse AKR1B3 and AKR1B7 as
well as the human AKR1B1 were tested and conﬁrmed using puri-
ﬁed recombinant proteins in a cell-free system in vitro (Kabututu
et al., 2009). Using a similar approach complemented with gain
and loss of function in endometrial cell lines, we have demon-
strated that the AKR1B1 was a functional PGFs in the human
endometrium (Bresson et al., 2011). In the present study, we have
investigated further the regulation of PGF2α production by differ-
ent stimulators and inhibitors as well as the promoter cis-elements
responsible for IL-1β response in human endometrial cell lines.
Finally, we have studied the association between AKR1B1 and
PGF2α production in representative tissues where PGF2α was
found to exert physiological action in vivo. We have evaluated
the potential of different AKR1B1 inhibitors (ARI) to alter PGs
production in living cells and in fresh endometrial tissues under
normal and high glucose conditions.
MATERIALS AND METHODS
REAGENTS
RPMI 1640 culture medium without phenol, Superscript II
reverse transcriptase, TRIzol, lipofectamine 2000, and pCR3.1
vectors were purchased from Invitrogen (Life technologies, ON,
Canada). TAQ DNA polymerase and buffer used for polymerase
chain reaction were from NEB (New England Biolabs, ON,
Canada). RiboMax polymerase kit for siRNAs was purchased from
Promega (Madison, WI, USA). Qiaquick gel extraction kit and
TA cloning pDrive vector were from Qiagen (Mississauga, ON,
Canada). All oligonucleotide primers were chemically synthesized
by Integrated DNA Technologies (IDT) (Coralville, IA, USA).
[α-32P]dCTP radioactivity was bought from PerkinElmer Life Sci-
ences (Markham,ON,Canada). Bright Star-Plus nylon membrane
and UltraHyb solution were purchased fromAmbion Inc. (Austin,
TX, USA). The rabbit COXs antibodies were kindly provided
by Dr S Kargman (Merck, QC, Canada), rabbit anti-Phospho-
cPLA2 (Ser505) was from Santa Cruz biotechnology (Santa Cruz,
CA, USA) and AKR1C3 was from Abcam Inc. (Cambridge, MA,
USA). Goat anti-rabbit horse-radish peroxidase-conjugated IgG
was bought from Jackson Immunoresearch Laboratories (West
Grove, PA, USA). The Western Lightning™Chemiluminescence
Reagent Plus was purchased from PerkinElmer (Woodbridge,ON,
Canada). Arachidonic acid (AA), and AL-8810 were from Cay-
man Chemicals (Ann Arbor, MI, USA) and recombinant human
IL-1βwas purchased fromResearch andDiagnostic Systems (Min-
neapolis, MN, USA). Aldose reductase inhibitors (ARIs), [ponal-
restat (Statil), Alrestatin, and EBPC] were from Tocris Bioscience
(Ellisville, MO, USA).
FIGURE 1 | Prostaglandin F2α and E2 biosynthetic pathways. In order
to generate PGF2α, AKR1B1 must team up with other constitutive and
inducible enzymes involved in the production of PGH2, the common
precursor of all PGs. Among those, we have found that cPLA2 liberating AA
from membrane phospholipids, COX-2, AKR1B1, and mPGES-1 are
inducible by the cytokine IL-1β. AKR1B1 apparently works with both COX-1
and COX-2 producing PGH2 to generate PGF2α whereas mPGES-1
preferentially associates with COX-2 to generate PGE2. Both epithelial and
stromal cells exhibit PGF2α responsiveness and stimulation or inhibition of
the FP receptor alters the production of both PGE2 and PGF2α through
action at several steps of the PG biosynthesis cascade.We also present in
this ﬁgure the PG transporters PGT also known as solute carrier SLCOA1
and MRP4 the multidrug resistance protein 4 or ABCC4.
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FIGURE 2 | Influence of IL-1β on the main biosynthetic enzymes
associated with PGF2αproduction in human endometrial stromal
and epithelial cells. Human endometrial stromal (HIESC-2) and
epithelial (HIEEC-2) cells were grown to conﬂuence and treated with
IL-1β for 24 h in presence and absence of NS-398 to block COX activity.
PGs biosynthetic enzymes were analyzed byWestern blot [HIESC-2 (A);
HIEEC-22 (B)] and associated with PGF2α production HIESC-2 (C) and
HIEEC-22 (D).
CULTURED CELL MODELS
Human endometrial stromal (HIESC-2) and epithelial (HIEEC-
22) cell lines were immortalized using SV40 large T antigen
(Chapdelaine et al., 2006) and shown to exhibit most characteris-
tics of freshly isolated endometrial cells (Kang et al., 2004, 2006).
Bovine endometrial epithelial cells were immortalized using a sim-
ilar protocol and also presented most characteristics of freshly
isolated cells (Krishnaswamy et al., 2009,2010; Lacroix-Pepin et al.,
2011).Humanprostate smoothmuscle cells,humanartery smooth
muscle cells, human umbilical vein endothelial cells (Huvec),
and human cardiomyocytes cells were from ScienCell Research
Laboratories (Carlsbad, CA, USA).
NORTHERN BLOT
Northern blot analysis was performed as follows: total RNA
(∼20μg) was extracted with Trizol (Invitrogen, Life technolo-
gies, ON, Canada) from cultured endometrial cells, loaded on
a 1.2% formaldehyde-agarose gel and electrophoresed at 100V
in 1× MOPS buffer. After electrophoresis, RNA was transferred
overnight onto a nylon membrane in 10× saline-sodium cit-
rate (SSC). The AKR1B1, mPGES-1, COX-1, and COX-2 cDNA
probes were produced by digestion with restriction enzymes
of different plasmids containing the corresponding cDNAs
previously generated in our laboratory, each releasing a ∼500 bp
fragment. The resulting probes were labeled with [α-32P(dCTP
(3000Ci/mmol) using the Ready-To-Go DNA labeling Kit (GE
Healthcare Life Science, QC, Canada). Prehybridization (2–4 h)
and hybridization (overnight) were done at 45˚C using Ultra-
Hyb solution (Ambion Inc., Invitrogen, Life technologies, ON,
Canada). The blots were then washed at 65˚C twice for 15min
in 0.5× SSC and exposed for 24–48 h at −80˚C on BioMAx
ﬁlms PerkinElmer (Woodbridge, ON, Canada) to quantify the
hybridization signal intensity. Finally, 18S ribosomal RNA stained
with ethidium bromide was used to conﬁrm uniform loading of
RNA samples and a 32P-labeled oligonucleotide speciﬁc to 18S
ribosomal RNA was used as an internal standard for Northern
blot analysis.
WESTERN BLOT
Western blot analysis was performed as we described (Chapde-
laine et al., 2006). Brieﬂy, total proteins (∼20μg) extracted from
culture cells were loaded in each lane and electrophoresis done
on 10% SDS-PAGE followed by electrotransfer onto nitrocellulose
membrane (Bio-Rad laboratories, Mississauga, ON, Canada). The
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FIGURE 3 |Time course of gene expression and PGs production in
human endometrial stromal and epithelial cells following stimulation
with IL-1β. Human endometrial stromal (HIESC-2) and epithelial (HIEEC-2)
cells were grown to conﬂuence and treated with IL-1β for different periods up
to 24 h. Northern Blots analysis (A,B) was used for detection of AKR1B1,
COX-1/-2, mPGES-1 mRNAs expression.The production of PGs was evaluated
as a function of time in stromal (C) and epithelial (D) endometrial cells where
stimulation ofPGF2αprecedes that of PGE2 (P <0.05).
primary antibodies used for the present study were the rabbit
AKR1B1 (dilution 1/1000), COX-1 or COX-2 (dilution 1/3000),
cPLA2 (1/1000) and goat AKR1C3 (1/500) anti-serums. As an
internal control, the β-actin monoclonal antibody (1/5000, Sigma,
Mississauga, ON, Canada) was used. The goat anti-rabbit IgG
conjugated with horse radish peroxidase (HRP), rabbit anti-goat
IgG HRP or goat anti-mouse IgG HRP were used as secondary
antibodies. The chemiluminescence was analyzed with autoradi-
ography ﬁlms at optimal times of exposure following treatment of
the membranes with theWestern Lightning™Chemiluminescence
Reagent Plus (PerkinElmer Canada).
ANALYSIS OF AKR1B1 PROMOTER ACTIVITY
A nested PCR strategy was developed to generate a long ∼4.5 kb
promoter to study the regulation of theAKR1B1 gene (AF032455).
The promoter PCR fragments were ampliﬁed with PFU turbo
DNA polymerase (Stratagene, Agilent technologies, USA) and
cloned directly by fusion (Clontech, TAKARA Biocompany) in a
pGL3 basic vector (Promega) containing the ﬁreﬂy luciferase gene.
Constructs of AKR1B1 promoter of seven different lengths were
generated using restriction enzymes targeting unique sequences in
the long promoter. A short portion of the AKR1B1 promoter cor-
responding to the multiple stress response region (MSRR) −1710
to −1064 to the translation initiation ATG position was ampli-
ﬁed by PCR, cloned in a TA cloning vector (pDrive, Qiagen) for
sequencing and linked in a pGL3 vector (Promega) to the minimal
SV40 promoter. From this, additional constructs were produced
by deletion of the cis-elements corresponding to TONE and AP1
or ARE1 and 2. Stromal (HIESC-2) and epithelial (HIEEC-22)
cells were co-transfected with the lipofectamine 2000 transfection
agent (Invitrogen) and the different plasmid constructs possess-
ing the ﬁreﬂy luciferase reporter and a plasmid containing the
synthetic Renilla luciferase gene. After transfection, cells were
treated for 24 h with IL-1β (1ng/ml), and the promoter activ-
ity was expressed as the ratio of ﬁreﬂy luciferase to the renilla
luciferase using the Dual-Luciferase Reporter (DLR™) Assay Sys-
tem (Promega, Madison, WI, USA) using a Luminoskan Ascent
luminometer (ThermoElectron Corporation,Milford,MA,USA).
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FIGURE 4 | Analysis of AKR1B1 promoter activity involved in IL-1β
response in human endometrial cells. (A) Schematic representation of
different AKR1B1 promoter constructs and corresponding activity
following treatment of transfected stromal and epithelial cells treated
with IL-1β. (B) Nucleotide sequence of the AKR1B1 promoter MSRR
region (−1710 to −1064) showing the organization of the important
cis-elements TonE (NFκB), AP1 and anti-oxidant response elements 1
and 2 (ARE1 and ARE2). (C) Relative activity of MSRR cis-elements of
the AKR1B1 promoter following stimulation with IL-1β of transfected
stromal endometrial cells.
CELL TREATMENTS
HIESC-2 (passages 15–22) and HIEEC-22 (passages 15–22) were
cultured in RPMI 1640 without phenol red, containing 50 IU
penicillin-streptomycin supplemented with 10% whole FBS dur-
ing growth and 10% dextran-coated charcoal extracted FBS once
cells have reached conﬂuence and for transfection or treatments.
Knockdown transfection of cells with AKR1B1 speciﬁc siRNA was
performed with lipofectamine 2000 for 4 h in culture medium
without antibiotic. Unless speciﬁed, otherwise cells were treated
for 24 h with IL-1β (1 ng/ml) or other agents at speciﬁed concen-
trations in RPMI 1640 medium without serum. For Western blot
analysis (described above), the cells were grown in 24-well plates
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FIGURE 5 | Association between induction of AKR1B1 and
PGF2α production following cytokine stimulations in cells from
different human tissues. Cells from different human tissues were
grown to conﬂuence and treated with IL-1β or IL-1α 1ng/ml or TNFα
at 10 ng/ml for 24 h. The culture medium was recovered for assay of
PGF2α by EIA and protein from attached cells recovered forWestern
blot analysis of COX-2 and AKR1B1. (A) Prostatic smooth muscle
cells, (B) human artery umbilical smooth muscle cells (HUASMC),
(C) human cardiomyocytes, and (D) Human Umbilical Endothelial
cells (HUVEC).
whereas for Northern blots analysis (described above), cells were
in 6-well plates. At the end of the treatment period, the culture
medium was recovered and stored at −20˚C until evaluation of
PGF2α or PGE2production by EIAwhereas protein andRNAwere
extracted directly fromcellmonolayer at the bottomof 24-well and
6-well plates, respectively.
ENDOMETRIAL EXPLANTS CULTURE
Endometrial tissue was obtained either from biopsies collected
with an endometrial curette (Pipelle) and obtained from women
aged between 25 and 50 years. Informed consent for dona-
tion of anonymous endometrial samples was obtained before
tissue collection. The research protocol was approved by the
Ethics Committee on Human Research of Centre Hospitalier
Universitaire de Québec. Endometrial explants were prepared
from fresh biopsies as described previously (Bresson et al.,
2011). Endometrial explants were stimulated or not with IL-
1β in the presence or absence of the aldose reductase inhibitor
ponalrestat (100μM) under normal (5mM) or high glucose
(25mM) for 24 h.
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FIGURE 6 | Influence of different aldose reductase inhibitors on
PGF2α and PGE2 production in human and bovine endometrial
cells. Human endometrial stromal [HIESC-2 (A,B)] and human
[HIEEC-22 (C)] or bovine epithelial [bEEL (D)] cells were grown to
conﬂuence and treated with 1 ng/ml IL-1β (A–C) or 10μM arachidonic
acid (AA, D) for 24 h in presence and absence of increasing
concentrations of indicated aldose reductase inhibitors. The culture
medium was recovered and PGE2 and PGF2α were assayed by EIA.
(A) Alrestatin (B–D) ponalrestat. Results are the mean±SEM of three
experiments run in triplicate.
MEASUREMENT OF SORBITOL
We have developed a LC/MS/MS procedure for quantitative mea-
surement of sorbitol generated in brieﬂy, the culture medium
was removed for estimation of PGE2 and PGF2α and sorbitol
was extracted from explants by mixing with lysis buffer (200μl),
methanol (600μl), chloroform (200μl), and water (500μl). The
mixturewas centrifuged for 5min at room temperature and 100 μl
of the upper phase was evaporated with a turbo-vap at 45˚C for
30min. The pellet was resuspended with 200 μl of Pyridine 10%:
anhydride acetic acid 10% in acetonitrile and brought at 70˚C
for 45min. After drying samples were diluted in 100μl metha-
nol/water (1:1) containing 5mM ammonium acetate. The sam-
ples were spikedwith Sorbitol-d8 (Omicron Biochemicals Inc., IN,
USA) also used for establishment of a standard curve and analyzed
on an Applied Biosystems API-5000 LC/MS/MS. The procedure
was optimized to minimize interference with sugars and alcohols
such as glucose, fructose, galactose, myoinositol, and galactitol.
PGE2 AND PGF2α EIA
PGE2 and PGF2α were assayed by competitive EIA using
acetylcholinesterase-linked PG tracers (Cayman, Ann Arbor, MI,
USA) as described previously (Asselin et al., 1996).
STATISTICAL ANALYSIS
Data were analyzed by One or Two way ANOVA with Bonferroni
as post hoc test with 95% conﬁdence intervals using GraphPad
Prism 5 program. For data with less than three columns a two-
tailedunpaired t testwith 95%conﬁdence intervalswas performed
using GraphPad Prism 5 program. Data are presented as the
mean± SEM. Each experiment was repeated three times unless
speciﬁed otherwise. Values were considered statistically signiﬁcant
for P < 0.05.
RESULTS
While glucose and oxidized lipids are passive stable substrates
for AKR1B1, generation of PGF2α requires the generation of the
unstable PGH2 precursor within the producing cell (Figure 1).
Figure 2 illustrates that upon stimulation by IL-1β, the rate lim-
iting enzymes cPLA2 releasing AA from membranes phospho-
lipids, COX-2 generating the PGH2 precursor and AKR1B1 are
all increased in both endometrial stromal (A) and epithelial (B)
cells. The production of PGF2α is also increased following IL-1β
stimulation, a response blocked by the COX-2 selective inhibitor
NS-398 (C and D). As was found previously (Pelletier et al., 1999;
Bresson et al., 2011), AKR1C3 is present only in epithelial cells
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FIGURE 7 | Influence of AKR1B1 and FP receptor inhibition or
stimulation on PG production in human endometrial stromal cells.
(A) Normal or AKR1B1 siRNA transfected human endometrial stromal
(HIESC-2) cells were grown to conﬂuence and treated with IL-1β for 24 h
and PGE2 and PGF2α were measured in the culture medium. (B) HIESC-2
cells were grown to conﬂuence and treated with IL-1β for 24 h in presence
and absence of increasing concentrations of the FP receptor antagonist
AL-8810, furthermore PGE2 and PGF2α were measured in the culture
medium. (C) HIESC-2 cells were grown to conﬂuence and treated for 24 h
with increasing doses of the PGF2α analog and FP receptor agonist
bimatoprost and PGE2 was measured in the culture medium.
and is not induced by IL-1β suggesting minimal contribution to
PGF2α production under these conditions.
The time course of PG biosynthetic enzymes activation fol-
lowing IL-1β stimulation was investigated at the mRNA level and
associated with PGF2α release (Figure 3). Note that there is basal
expression of AKR1B1 gene under non-stimulated conditions and
that there is serial transcription of biosynthetic enzyme genes
withAKR1B1 precedingCOX-2 precedingmPGES-1.Accordingly,
PGF2α release precedes that of PGE2 in both stromal and epithelial
cells (P < 0.05).
We have cloned theAKR1B1 promoter (∼4.5 kb) and generated
eight constructs to identify potential response elements sensitive
to IL-1β stimulation (Figure 4). IL-1β stimulates the AKR1B1
promoter activity from-583up in both endometrial stromal and
epithelial cells (Figure 4A). A MSRR containing two putative
antioxidant response elements (ARE) adjacent to TonE and AP1
previously identiﬁed for the mouseAKR1B3 (Nishinaka andYabe-
Nishimura, 2005) was also identiﬁed for the human AKR1B1 gene
at −1710 to −1064 (Figure 4B). The human MSRR region was
analyzed in a vector containing a minimal promoter SV40 to iden-
tify putative cis-elements of the AKR1B1 gene promoter activity
involved in IL-1β response (Figure 4C). TheAREsARE1 andARE2
appear particularly efﬁcient to confer IL-1β response and may
explain the quick activation of AKR1B1 and PGF2α production
observed in Figure 3.
The PGF synthase activity of AKR1B1 and its stimulation by
IL-1β and TNFα was investigated in cultured cells isolated from
different human tissues (Figure 5). In addition to endometrial
cells where we made our initial discovery, we have found that IL-
1β and to a lesser extent TNFα stimulated AKR1B1, COX-2, and
PGF2α production in prostatic smooth muscle cells (A), arter-
ial smooth muscle cells (B), cardiomyocytes (C), and umbilical
endothelial cells (HUVEC D). In the last two models, the observed
increase in PGF2α production appeared to result from increased
COX-2 expression coupled with already high preexisting levels of
AKR1B1.
We have compared the inhibition potential of three aldose
reductase inhibitors; alrestatin, EBPC (not shown) and ponalre-
stat on human endometrial cells and tested the latter on bovine
endometrial epithelial cells (Figure 6). Alrestatin did not have
any effect on PGF2α production (Figure 6A). EBPC inhibited
PGF2α production with an apparent EC50 around 10 μM (not
shown) whereas ponalrestat was the most potent with an EC50
of 1 μM (Figure 6B). Ponalrestat also inhibited PGF2α in human
(Figure 6C) and bovine (Figure 6D) endometrial epithelial cells
albeit with reduced efﬁciency exhibiting an EC50 of 50μM. Inter-
estingly, ARIs not only inhibited PGF2α but also PGE2 in all cell
models.
The potential non-selective inhibition of several components
of PG biosynthesis by ARIs was investigated further (Figure 7).
When AKR1B1 expression was knocked down by siRNA, similar
observation of concurrent inhibition of PGF2α and PGE2 was
observed (Figure 7A) suggesting potential interactions between
the two biosynthetic pathways. The possibility that AKR1B1 could
exert positive regulation of PGE2 production through PGF2α and
its FP receptorwas tested (Figure 7B). Interestingly,whenAKR1B1
and PGF2α production are stimulated with IL-1β, PGF2α, and the
concomitant increase of PGE2 is reduced in presence of the FP
receptor antagonist AL-8810 suggesting that PGF2α was able to
stimulate its own and PGE2 production. The latter hypothesis
was tested using the PGF2α analog bimatoprost which stimulated
PGE2 release in a dose dependent manner (Figure 7C).
Finally, the relative afﬁnity and potential competition between
the PGFS and polyol pathway was tested under close to in vivo
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FIGURE 8 | Influence of glucose concentration on the relative
production of sorbitol and PGF2α in fresh explants from human
endometrium. Endometrial explants were prepared from fresh
endometrial biopsies, cultured for 24 h, and stimulated with IL-1β (10 ng/ml)
in presence or absence of Statil (ponalrestat, 100μM) under normal (LG)
5mg/ml or High (HG) 25mg/ml glucose concentrations. PGF2α production
was measured by EIA. Results from two different experiments are
illustrated.
conditions (Figure 8). Fresh endometrial explants were treated
with IL-1β in presence and absence of ponalrestat under nor-
mal and high glucose conditions. Interestingly, IL-1β previously
demonstrated to increase AKR1B1 expression increased PGF2α or
sorbitol production depending on normal or high glucose con-
ditions respectively. This demonstrates that PGF2α and sorbitol
are formed competitively depending on the relative availability of
AKR1B1 substrates.
DISCUSSION
Prostaglandins are important regulators of female reproductive
function and contribute to gynecological disorders. Normal men-
struation depend on an equilibrium between vasoconstrictors
such as PGF2α (Lockwood and Schatz, 1996; Sales and Jab-
bour, 2003a) and vasodilators such as PGE2 or nitric oxide (NO)
(Tschugguel et al., 1999). Excessive production of contracting
prostaglandins create an ischemia-reperfusion response causing
painful menstruation or dysmenorrhea (Okazaki et al., 2005)
whereas increased vasodilatation leads to abundant menstrual
bleeding (Sales and Jabbour, 2003b). NSAIDs represent the most
important and widely used drugs on the market and they are
all efﬁcient to treat menstrual disorders at some level. However
these drugs act at an early step of biosynthesis common to all PGs
and not only the isotype responsible for the pathological response
(Figure 9). Because of its notorious role on inﬂammation and
pain, the biosynthetic pathway leading to PGE2 has been stud-
ied extensively, but that of PGF2α is poorly documented. The
data presented in this manuscript address the conditions regulat-
ing the newly identiﬁed PGFS activity of AKR1B1. In the human
endometrium, it has been reported that production of PGF2α
is higher in late secretory and menstrual periods of the men-
strual cycle (Downie et al., 1974). Accordingly, both AKR1B1 and
AKR1C3 enzymes are present in the endometrium throughout the
menstrual cycle. By contrast with AKR1B1expressed in both stro-
mal and glandular epithelial cells and modulated in association
with endometrial PGF2α production, AKR1C3 expression is con-
stant and completely absent in stromal cells as was reported pre-
viously (Pelletier et al., 1999; Zakharov et al., 2010). The absence
of the only currently accepted human PGFS AKR1C3 in stromal
cells was surprising because we and others have shown that human
endometrial stromal cells produce high levels of PGF2α (Huang
et al., 1998; Chapdelaine et al., 2006; Kang et al., 2006). Because
of a similar ﬁnding in the bovine endometrium and our identiﬁ-
cation of AKR1B5 as a functional PGFS in that system (Madore
et al., 2003), we hypothesized that the human AKR1B1, could also
express PGFS activity in the human endometrium. Our initial
studies showing the association between AKR1B1 expression and
PGF2α production was conﬁrmed unequivocally in the human
endometrium using gain and loss of function approaches (Bres-
son et al., 2011). The PGF synthase activity of AKR1B1 and other
members of this family is now acknowledged by leaders in the ﬁeld
of prostaglandin synthases (Nagata et al., 2011; Smith et al., 2011;
Watanabe, 2011).
In the present study we highlight the necessary co-activation
of genes of the PG biosynthesis pathway to provide the PGH2
precursor substrate to AKR1B1 in order to generate PGF2α. This
is in clear contrast with detoxiﬁcation or aldose reductase activ-
ities of AKR1B1 for which substrates are provided by extracellu-
lar sources (glucose) or as byproducts of intracellular reactions
(oxidized lipids). Endometrial cells express constitutively GLUT2
and GLUT3 and do not require insulin for glucose entry, as
such; the endometrium belongs to the category of tissues most
adversely affected by poorly controlled glucose levels occurring
during insulin resistance or diabetes. Figures 2 and 3 illustrate
that genes and proteins of the biosynthetic pathway are increased
in a time and dose dependent manner to explain increased PGF2α
production following IL-1β stimulation.
In Figure 3 and then in Figures 6 and 7 we observe that PGE2
production closely follows that of PGF2α under both stimula-
tory and inhibitory conditions. We ﬁrst considered these results
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FIGURE 9 | Regulation of PGs of the relative PGE2 and PGF2α release
in endometrial cells. Following activation of endometrial cells with the
cytokine IL-1β, several enzymes leading to the production of PGF2α and
PGE2 exhibit increased expression and/or activity. Treatment of cells with
NSAIDs will inhibit the generation of PGH2 at the level of COX-1 and
COX-2, thus blocking the release of both PGF2α and PGE2 without an
alteration of the relative production of the two PGs. Inhibition of AKR1B1
(Continued)
FIGURE 9 | Continued
activity with ARIs will inhibit preferentially PGF2α release thus creating an
imbalance in favor of PGE2. However, decreased stimulation of the FP
receptor should down-regulate the production of PGE2. In presence of high
glucose concentration, the stimulation of AKR1B1 may be exacerbated, but
glucose should inhibit competitively PGF2α release in which case reduced
FP stimulation should also reduce PGE2 production. However, when
glucose concentration falls back to normal, high AKR1B1 levels would favor
PGF2α release and ischemic responses until PGE2 is able to compensate
through EP2 and bring back a silent condition where the balance between
PGF2α and PGE2 is re-established.
as artifact and resulting from defective experimental design. How-
ever, when we observed that inhibition of FP receptor prevented
the increase in PGE2 and that FP receptor stimulation alone was
sufﬁcient to stimulate PGE2 production, we proposed that there
was a positive feedback loop between PGF2α release and produc-
tion of PGE2. A link between FP activation and increased PG
production could have been anticipated from previous observa-
tions in a human endometrial model (Jabbour et al., 2005; Sales
et al., 2008) and from our own observations in bovine endometrial
cells (Krishnaswamy et al., 2010) given that FP and the oxytocin
receptor (OT) share the same signal transduction systems. How-
ever, this is theﬁrst evidenceof a speciﬁc linkbetweenFPactivation
and PGE2 production within a homogeneous cell system with
potential physiological and pathological relevance. If we hypothe-
size that PGE2 acting on EP2 receptors and PGF2α acting through
FP work as a dyad with opposite actions in the reproductive sys-
tem, just like the thromboxane/prostacyclin dyad in the vascular
system, then the interactions between the two systems are not only
probable but also necessary.
Prostaglandins work like a micro endocrine system sensing
altered conditions and reestablish locally, optimal conditions for
tightly regulated events such as ovulation or recognition of preg-
nancy in the reproductive system or hemostasis in the vascular
system. In this respect, PGF2α exhibits vasoconstrictive and pro-
thrombotic responses comparable to thromboxane with the addi-
tional feature that the PGF2α molecule is chemically stable and
remains active until catabolism by prostaglandin dehydrogenase,
usually through a single passage in the lung. By contrast PGE2/EP2
trigger a vasodilator response with anti thrombotic action similar
to prostacyclin but again PGE2 is much more stable than PGI2.
Thus it is important to tightly regulate the relative production and
release of PGF2α and PGE2 and in this respect; our identiﬁcation
of a feedback loop between PGF2α and PGE2 within endometrial
cells has important implications for the observed complications
associated with over-expression of AKR1B1. We have initiated the
characterization of the AKR1B1 promoter and identiﬁed a MSRR
containing twoputativeAREs adjacent toTonE andAP1. TheAREs
ARE1 and ARE2 appear to be involved in IL-1β response, which
supports the local sensing functions of PGs to which AKR1B1
is now a contributing component. The MSRR portion of the
AKR1B1 promoter will have to be investigated further under IL-1β
stimulation to identify the trans-factors associated with the pro-
duction of PGF2α. Because of its reported interaction with AREs,
NRF2 also known as Nuclear factor (erythroid-derived 2)-like 2
(NFE2L2) is a likely candidate to link increased PGF2α release
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under inﬂammatory conditions (Nishinaka and Yabe-Nishimura,
2005).
Clinical and pathological implications: Prostaglandins are
important regulators of female reproductive functions. In this
respect, gene inactivation studies in the mouse have shown that
COX-2 and EP2 null mice share similar phenotypes where ovu-
lation and implantation are impaired (Lim et al., 1997; Kennedy
et al., 1999). The PGF2α/FP system is much less documented than
that of PGE2, but the group of Jabbour in Edinburg has doc-
umented its involvement in endometrial pathologies including
menstrual disorders and endometrial cancer (Milne and Jabbour,
2003; Jabbour and Sales, 2004; Sales et al., 2004; Jabbour et al.,
2005, 2006; Abera et al., 2010; Catalano et al., 2011) while we
(Breuiller-Fouche et al., 2010; Phillips et al., 2011) and others
(Olson and Ammann, 2007) associate it with premature deliv-
ery. With that in mind, it is likely that AKR1B1 contribute to these
pathologies and conversely conditions where AKR1B1 is affected
such as diabetes and metabolic syndrome may exhibit a speciﬁc
prognosis pattern in affected women. In addition, we claim that
the female reproductive system constitutes a powerful model to
understand the contribution of PGs to physio-pathological con-
ditions in other systems. This is supported by Figure 5 showing
the relation between AKR1B1 and PG biosynthetic enzymes in
response to IL-1β and their association with PGF2α production in
smooth muscles, cardiomyocytes, and endothelial cells. This is all
the more important as AKR1B1 known to be highly responsive to
diverse physiologic andpathologic conditions and itsmultiple sub-
strate processing ability combine to create complex combinations
well illustrated in Figure 8. For instance, PGF2α has been associ-
ated with cardiac hypertrophy (Lai et al., 1996) and a new hamster
AKR1B was identiﬁed and proposed to contribute to cardiomy-
opathy through PGF2α release (Sakamoto and Sugamoto, 2011).
Moreover, knowing that high glucose induce AKR1B1 expression
we see that as long as glucose levels remain high, there will be
little increase in PGF2α release, but when glucose goes down,
the high levels of AKR1B1 will generate increased production of
PGF2α (Figure 9). In turn, high PGF2α will trigger pro-ischemic
responses (Yuhki et al., 2010) that fortunately will be compen-
sated by the feedback loop release of PGE2 exerting opposite action
thus bringing back homeostasis (Mandal et al., 2005). Normal ten-
sion results from the action of EP2 opposing FP receptors in the
vascular system, but adjacent tissues also express other EP recep-
tors responsible for inﬂammation and pain. Therefore the relative
silent condition resulting from PGE2 compensation of overpro-
duction of PGF2α by AKR1B1 will likely generate pain or hyperal-
gesia increasing the probability to take NSAIDs. Not that far ago,
the best pain killer on the market with minimal gastrointestinal
toxicity was rofecoxib (Vioxx), the most powerful medication to
date eradicating pain by reducing mPGES-1 generated PGE2. If
someone taking Vioxx was under the silent (increased AKR1B1)
condition, then the compensatory PGE2/EP2 would not be avail-
able to counteract the ischemic response to PGF2α thus increasing
the risks of heart failure. Interestingly, even after adjustment of risk
factors, reexamination of Vioxx events (Baron et al., 2008) reveal
that people suffering from type two diabetes were eight timesmore
at risk to die from Vioxx than non-diabetics. By contrast people
taking both Vioxx and Aspirin, thus blocking the AKR1B1 gener-
ated PGF2α were protected. Therefore, it is worth investigating if
and how AKR1B1 potentially contributed to the failure of Vioxx.
In conclusion, the ability of AKR1B1 to release PGF2α brings
a new angle to look at mechanisms responsible for pathophysi-
ologic conditions in the woman reproductive and other systems
especially in association with diabetes.
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